Phase 2, open-label, noncomparative clinical trial evaluating safety and efficacy of posaconazole in pediatric patients with proven/probable invasive aspergillosis or possible invasive fungal disease

Antimicrobial Agents and Chemotherapy 2026 Open access

Read full text
Authors: Hyoung Jin Kang, Antonio Carlos Arrieta, Catharina Dhooge, Ágnes Kelemen, Mercedes Macías-Parra, Lourdes Aranda, Yu. V. Dinikina, Imad Kassis, Simone Cesaro, Aimee Shepherd, Arvind K. Shah, Tiffany Mackey
+2 more Hetty A. Waskin, Matthew G. Johnson
DOI: 10.1128/aac.01305-25
Cited by: 0
References: 61

Abstract

ABSTRACT Children with invasive aspergillosis (IA) experience significant morbidity and mortality. Posaconazole is a broad-spectrum triazole antifungal agent indicated for IA treatment in adolescents and adults. A phase 2, open-label, noncomparative, multinational clinical trial in pediatric participants (2-to-

Fields of Study & Subjects

Antifungal resistance and susceptibility Fungal Infections and Studies Pharmaceutical studies and practices

Publication details

Journal / source
Antimicrobial Agents and Chemotherapy
Volume
70
Issue
3
Pages
e0130525–e0130525
Publication date
27 January 2026
Language
EN